Role of Immune Checkpoint Inhibitor Therapy in Advanced EGFR-Mutant Non-Small Cell Lung Cancer

Area of Science:

• Oncology
• Immunotherapy
• Genetics

Background:

• Advanced non-small cell lung cancer (NSCLC) treatment has evolved with targeted therapies and immune checkpoint inhibitors (ICIs).
• Epidermal growth factor receptor (EGFR) gene mutant (EGFRm) NSCLC patients benefit from newer tyrosine kinase inhibitors (TKIs), but disease progression necessitates further therapeutic options.
• ICI therapy has improved outcomes in EGFR wild-type (EGFRwt) NSCLC, but its role in EGFRm NSCLC is debated due to initial findings of inferiority and toxicity concerns with combination therapies.

Purpose of the Study:

• To review current and ongoing clinical studies of ICI therapy in advanced EGFRm NSCLC.
• To discuss the biological differences in EGFRm NSCLC tumors and their tumor microenvironment (TME) that may impact ICI efficacy.
• To provide an overview of existing therapies, clinical trials, and research avenues for improved outcomes in advanced EGFRm NSCLC.

Main Methods:

• Review of previous and ongoing clinical studies involving ICI therapy in advanced EGFRm NSCLC.
• Analysis of tumor biology and TME characteristics specific to EGFRm NSCLC.
• Synthesis of information on current treatment paradigms, clinical trial results, and emerging research directions.

Main Results:

• ICI monotherapy has shown inferiority compared to EGFR TKI therapy in the first-line setting and chemotherapy in the second-line setting for EGFRm NSCLC.
• Combination therapies of ICI and EGFR TKIs have been associated with increased toxicities.
• Ongoing studies are investigating combination therapies, including dual-ICI blockade and combinations with chemotherapy and angiogenesis inhibitors, with some preliminary positive signals.

Conclusions:

• Despite initial challenges, research into ICI therapy for advanced EGFRm NSCLC is active, focusing on understanding tumor biology and TME to enhance efficacy.
• Combination strategies, including dual-ICI blockade and multi-agent regimens, are under investigation.
• Novel approaches are being explored to improve clinical outcomes for patients with advanced EGFRm NSCLC receiving ICI therapy.